Etidronate

• CAT Number: A000482
• CAS Number: 2809-21-4
• Molecular Formula: C2H8O7P2
• Molecular Weight: 206.03
• Purity: ≥95%
• Target: protein tyrosine phosphatase
• Storage: 3 years -20C powder
• IUPAC Name: (1-hydroxy-1-phosphonoethyl)phosphonic acid
• InChI: InChI=1S/C2H8O7P2/c1-2(3,10(4,5)6)11(7,8)9/h3H,1H3,(H2,4,5,6)(H2,7,8,9)
• InChIKey: DBVJJBKOTRCVKF-UHFFFAOYSA-N
• SMILES: CC(O)(P(=O)(O)O)P(=O)(O)O

Etidronate (CAT: A000482) is a non-aminobisphosphonate compound with versatile pharmacological properties. It exhibits protein tyrosine phosphatase (PTP) inhibitory activity, making it valuable for treating Paget’s disease and preventing heterotopic ossification. The mechanism of action includes direct inhibition of osteoclastic bone-resorbing activity, induction of apoptosis, and disruption of actin rings in osteoclasts. In experimental studies, Etidronate has demonstrated efficacy in suppressing mechanical allodynia and preserving bone mineral density in arthritic animal models. Its multifaceted activities contribute to its relevance in pharmaceutical and medical research, particularly in bone health and pain management studies.

Overview of Clinical Research

Etidronate is a bone resorption factor inhibitor and a DNA synthesis inhibitor. The phase I trial in Bone metastases in Russia (IV) (NCT02673060) is ongoing.

Reference

1.Hiroi-Furuya, E., et al. "Etidronate (EHDP) inhibits osteoclastic-bone resorption, promotes apoptosis and disrupts actin rings in isolate-mature osteoclasts." Calcified tissue international 64.3 (1999): 219-223.
2.Kawabata, Atsufumi, et al. "Antiallodynic effect of etidronate, a bisphosphonate, in rats with adjuvant-induced arthritis: involvement of ATP-sensitive K+ channels." Neuropharmacology 51.2 (2006): 182-190.
3.Funayama, H., et al. "Inhibition of inflammatory and bone-resorption–inhibitory effects of alendronate by etidronate." Calcified tissue international 76.6 (2005): 448-457.
4.Tamura, Kazuhiro, et al. "Effect of etidronate on aortic calcification and bone metabolism in calcitoriol-treated rats with subtotal nephrectomy." Journal of pharmacological sciences 99.1 (2005): 89-94.
5.Tamura, Kazuhiro, et al. "Prevention of aortic calcification by etidronate in the renal failure rat model." European journal of pharmacology 558.1-3 (2007): 159-166.